Celleron Therapeutics - Management Team

Nicholas La Thangue, Founding Director.

He has over 20 years of experience in biotechnology and healthcare. He founded Prolifix in 1995, a successful spin-out from the UK Medical Research Council, focussed on cancer drug discovery and was CSO until its merger with the Scandinavian oncology company TopoTarget. He acted as Chief Business Development Officer in TopoTarget, and was responsible for completing a number of significant deals with both large and mid size companies. La Thangue has extensive scientific, commercial and financing experience derived from the biotechnology sector. He is Professor of Cancer Biology at the University of Oxford, and was previously Cathcart Professor of Biochemistry at the University of Glasgow, and before that a scientist at the Medical Research Council. He studied for his Ph.D. at University College London and carried out post-doctoral work at Imperial College London. He is a Fellow of the Royal Society of Edinburgh, a Fellow of the Academy of Medical Sciences and a Member of EMBO. He has authored over 150 publications and is an inventor on an extensive number of granted patents.

David Kerr, Founding Director.

He has over 20 years of experience of clinical trials and has overseen the clinical progression of several successful oncology drugs. He is Rhodes Professor of Cancer Therapeutics and Clinical Pharmacology at the University of Oxford and was Director of the National Translational Cancer Research Network (NTRAC). He has an international reputation for treatment of and research into colorectal cancer. The quality of his work has been recognised by the award of several international prizes, and the first Nye-Bevan award for innovation. Professor Kerr is a member of the National Cancer Taskforce, President-elect of the European Society of Medical Oncology, constructed a 20 year plan for Scotland’s National Health Service, and was Editor-in-Chief of Annals of Oncology, Europe’s premier medical oncology journal. Professor Kerr has extensive experience of the healthcare industry. He previously founded Cobra Therapeutics, which was subsequently merged with Therexsys, and has consulted extensively for biotechnology and pharmaceutical companies. He has authored over 200 publications and patents on cancer clinical trials and new oncology drugs.